CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 39 enrolled
Drug / intervention
Razadyne +1 moredrug
Likely dose
Razadyne 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00566735
NCT00566735Phase 3Completed
CompareCT.gov

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

Massachusetts General Hospital·interventional·Posted Dec 4, 2007·Updated Dec 3, 2012

In Brief

A Phase 3 clinical trial evaluating Razadyne and Placebo for Major Depression and 2 related conditions. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depression, Bipolar Depression, Schizoaffective Disorder
CountriesUnited States
CollaboratorsOrtho-McNeil Janssen Scientific Affairs, LLC

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 4, 2007
Enrollment StartJul 1, 2004
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.6 years ago

Interventions

Razadynedrug

The starting dose of study medication is 4 mg twice a day

Placebodrug

4 mg, 2 times a day